While shares of small-cap food biotech Senomyx (NASDAQ:SNMX) have pulled back almost 30% from my last piece as enthusiasm has faded in the wake of securing GRAS determination for key product Sweetmyx S617, they're still up more than 50% from my Top Idea write-up in 2013.
More importantly, Senomyx continues to make significant progress with
its developmental and commercial programs. Although Senomyx shares may
well get batted around this year as the market vacillates between
risk-on and risk-off, the significant potential of the company's sweet
and savory programs is a good reason to buy or continue holding the
shares.
Continue here:
A Quietly Busy Senomyx
No comments:
Post a Comment